First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.

A, Scherpereel; S, Antonia; Y, Bautista; F, Grossi; D, Kowalski; G, Zalcman; AK, Nowak; N, Fujimoto; S, Peters; AS, Tsao; AS, Mansfield; S, Popat; X, Sun; R, Lawrance; X, Zhang; MJ, Daumont; B, Bennett; M, McKenna; P, Baas

doi:10.1016/j.lungcan.2022.03.012

Public

First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.

Shared by NobleBlocks on Mar 21, 2022 • 12:00 AM UTC

Authors:

Scherpereel A

Antonia S

Bautista Y

Abstract

<h4>Objective</h4>In CheckMate 743 (NCT02899299), nivolumab + ipilimumab significantly prolonged overall survival in patients with unresectable malignant pleural mesothelioma (MPM). We present patient-reported outcomes (PROs).<h4>Materials and methods</h4>Patients (N = 605) were randomized to nivolu...

Subject

Immunotherapy

Quality of life

Overall Survival

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!